With the successful PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) and OncoMRD (Monitoring Residual Disease) launch, OncoDxRx is sending a clear message: OncoDxRx’s exclusive precision functional genomics technologies now are capable of delivering decisive and actionable results in the most challenging clinical conditions.

PGA and OncoMRD are the latest and most technologically advanced assays in the pipelines of OncoDxRx, designed to complement the current NGS-based biomarker testing and MRD tests. Developed by OncoDxRx, both technologies represent the pinnacle of modern liquid biopsy transcriptomic profiling, engineered to outperform ctDNA-based assays.

One of their standout features is their abilities to be quickly implemented and operated on any qPCR machine in all molecular diagnostic labs, making it highly interoperable even in the most challenging environments.

A key advantage of PGA and OncoMRD lies in the patient’s own gene signature, which combines both tumor and non-tumor microenvironment biomarkers. This allows the assays to detect and track gene activities in “all” tissue context where other systems could miss and fail. Their onboard data analytics can identify the best treatment option and detect residual tumor activity, respectively, ensuring near-flawless accuracy in therapeutic selection and monitoring.

These technologies’ in silico data analytics are equally revolutionary. The digital computation is powered by multilayered data fusion, delivering significantly extended operational accuracy and detection power. Combined with the lowest cost and quickest turnaround, these assays allow labs to maintain the highest efficiency even at maximum volume.

To ensure compatibility across various platforms, PGA and OncoMRD are designed to be operated on all regular quantitative qPCR instruments, greatly enhancing their operational versatility. They can be deployed not only on OncoDxRx’s platforms but are also available for partnership and can adapt easily to other existing platforms.

Compared to the standard of care ctDNA tests, OncoDxRx’s cfmRNA-based technologies offer superior exclusivity, improved accuracy, and greater resilience against market competition. They are capable of performing in the third-world environments—a common challenge for those high-end NGS biomarker and MRD tests.

The development of PGA and OncoMRD is not just a technological leap but a strategic move to maintain OncoDxRx’s leadership in precision functional genomics. With the growing presence of cancer patients across global theaters, the need for highly effective diagnostic systems like PGA and OncoMRD has become increasingly critical.

By integrating PGA and OncoMRD tests into its test menu, OncoDxRx signals its commitment to maintaining a leading role in precision oncology and protecting its patients especially those unresponsive to precision medicine. Combining precision, power, and technological innovation, both PGA and OncoMRD are set to reshape the balance of power in the fight against cancer.